Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cryo Cell International (CCEL) Capital Expenditures (2016 - 2025)

Cryo Cell International (CCEL) has disclosed Capital Expenditures for 16 consecutive years, with $67226.0 as the latest value for Q4 2025.

  • On a quarterly basis, Capital Expenditures rose 705.29% to $67226.0 in Q4 2025 year-over-year; TTM through Nov 2025 was $230475.0, a 90.41% decrease, with the full-year FY2025 number at $230475.0, down 90.41% from a year prior.
  • Capital Expenditures was $67226.0 for Q4 2025 at Cryo Cell International, up from $38788.0 in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $11.2 million in Q3 2022 to a low of -$25011.0 in Q4 2022.
  • A 5-year average of $1.2 million and a median of $293481.5 in 2021 define the central range for Capital Expenditures.
  • Peak YoY movement for Capital Expenditures: skyrocketed 70551.85% in 2021, then tumbled 108.93% in 2022.
  • Cryo Cell International's Capital Expenditures stood at $279993.0 in 2021, then crashed by 108.93% to -$25011.0 in 2022, then surged by 6956.64% to $1.7 million in 2023, then plummeted by 99.51% to $8348.0 in 2024, then soared by 705.29% to $67226.0 in 2025.
  • Per Business Quant, the three most recent readings for CCEL's Capital Expenditures are $67226.0 (Q4 2025), $38788.0 (Q3 2025), and $62408.0 (Q2 2025).